盐酸氟西汀每日用药与按需给药在早泄治疗中的比较研究

目的 比较盐酸氟西汀每日用药与按需给药在早泄治疗中的不同疗效.方法 早泄患者84例,随机分成A和B组,每组42例.A组患者每口服用盐酸氟两汀,20 mg/d.B组患者按需给药盐酸氟西汀,30 mg/次.两组患者连续口服3月后,比较其治疗前后的平均阴道内射精潜伏期、国际勃起功能指数(IIEF)问卷中的配偶性交满意度评分及治疗期间的不良反应.结果 两组患者平均阴道内射精潜伏期,患者及其配偶的性交满意度评分在治疗后均显著增加(P＜0.01),盐酸氟两汀按需给药在射精潜伏期和性交满意度评分上比每日用药好些,但没有显著差异(P＞0.05).按需给药不良反应少于每日用药.结论 盐酸氟西汀可有效治疗早泄,按需给药优于每日用药.     

舍曲林治疗无效的早泄患者应用达泊西汀的疗效观察

目的观察达泊西汀用于舍曲林治疗无效的早泄患者的疗效。方法收集2017年10月至2020年10月应用舍曲林(50mg)治疗早泄的患者,按照治疗早泄的疗效分为舍曲林治疗有效组(有效组)和舍曲林治疗无效组(无效组),洗脱后两组均改用达泊西汀30mg按需口服,观察两组阴道内射精潜伏时间(IELT)、早泄评估量表(PEP)、临床总体印象评分(CGIC)及不良反应发生情况。结果 106例患者中,97例患者完成随访。有效组(56例)与无效组(41例)患者治疗前各项指标无统计学差异(P0.05),治疗后4、12周两组患者IELT、PEP、CGIC均较基线值明显改善,两组疗效相似,无明显的统计学差异(P0.05)。两组不良反应发生率无明显差别。结论口服舍曲林无效的患者改服达泊西汀仍然有较好的效果;达泊西汀治疗早泄的效果与舍曲林是否有效无关。     

氟西汀、帕罗西汀和氯丙米嗪治疗早泄的临床研究

目的 :比较氟西汀、帕罗西汀、氯丙米嗪治疗早泄的疗效和副作用。方法 :分别以口服氟西汀 2 0mg/d、帕罗西汀 2 0mg/d和氯丙米嗪 5 0mg/d治疗早泄 ,疗程 4周 ,通过问卷调查三种药物的疗效及副作用。 结果 :74例患者完成疗程 ,三种药物治疗早泄的有效率氟西汀为 70 .4 %、帕罗西汀为 73.0 %、氯丙米嗪为 76 .1% ,差异无统计学意义 (P >0 .0 5 )。其中氟西汀的副作用发生率较低。结论 :治疗早泄氟西汀能提高患者依从性 ,间接提高治疗成功率     

达泊西汀治疗早泄的临床观察

目的了解达泊西汀(第一个被批准用于治疗早泄的药物)治疗中国男性早泄患者的疗效。方法本研究为前瞻性、开放的自身对照研究。收集2014年2~4月在我院门诊就诊的早泄患者,所有患者接受30mg×6粒达泊西汀治疗,4周后随访,记录患者用药情况及副作用,比较用药前后患者阴道内射精潜伏时间、评估早泄量表及临床总体印象评分的变化。结果应用临床总体印象评分,63.6%(21/33例)的患者报告有效;患者治疗前阴道内射精潜伏时间平均为0.88min,治疗后平均为2.54min。副作用包括头晕、恶心、失眠、腹泻及射精困难,均轻微,可耐受。结论达泊西汀治疗中国早泄患者安全、有效。     

伊木萨克片联合盐酸氟西汀治疗早泄的临床研究

目的 研究伊木萨克片和盐酸氟西汀联合治疗早泄的可行性和效果.方法 将114例早泄患者随机分为3组,每组38例.A组患者单用伊木萨克片,1.5 g/d;B组患者单用盐酸氟西汀,20 mg/d;C组患者同时服用伊木萨克片和盐酸氟西汀,剂量同A、B组,连续服用4周.比较3组治疗前后的平均阴道内射精潜伏期(IELT)、国际勃起功能指数(IIEF)问卷中的患者及配偶性交满意度评分,观察治疗期间的不良反应.结果 114例早泄患者全部完成临床研究,所有患者平均IELT、患者及其配偶的性交满意度评分在治疗后较治疗前均显著增加,差异具统计学意义(P<0.01),单用盐酸氟西汀B组患者的IELT和性交满意度评分略好于单用药伊木萨克片A组,但两组间差异无统计学意义(P>0.05).联合用药C组患者的IELT和性交满意度评分则显著高于单用药A组和B组,差异均具有统计学意义(P<0.05).联合用药患者出现不良反应7例(18.4%),与单用药组比较差异无统计学意义.结论 联合应用伊木萨克片和盐酸氟西汀治疗早泄,疗效显著高于单用两种药物.     

西酞普兰治疗早泄的临床观察

目的:探讨西酞普兰治疗早泄的临床疗效和安全性。方法:将2011年5月至2012年5月男科门诊就诊的80例早泄患者随机分为治疗组和对照组,每组40例。治疗组每天口服西酞普兰20 mg,对照组口服安慰剂,记录治疗前、治疗2周和4周后患者阴道内射精潜伏时间(IELT)和性交满意度分值。结果:治疗组治疗2、4周后IELT分别为(5.64±1.31)min和(7.12±1.56)min,均比治疗前[(0.91±0.18)min]明显延长(P均<0.01),且西酞普兰治疗4周后的IELT明显高于2周后(P<0.01);治疗组治疗2、4周后性交满意度分别为(6.1±1.3)分和(6.3±1.1)分,与治疗前[(2.5±0.8)分]相比有明显提高(P<0.01),而治疗2周和4周后性交满意度无显著性差异(P>0.05)。对照组治疗2、4周后IELT和性交满意度分别为(1.02±0.24)min、1.01±0.21 min和(3.0±1.1)分、(3.1±1.3)分,与治疗前[(0.95±0.17)min和(3.2±1.2)分]比较,均无显著性差异(P均>0.05)。结论:每天口服西酞普兰20 mg,对早泄患者IELT和性交满意度均有明显改善,西酞普兰治疗早泄具有较好的临床疗效和安全性。     

抗抑郁药物配合行为疗法治疗早泄的对照研究

为探讨盐酸氟西汀治疗早泄患者的疗效.我院收集43例门诊早泄病人,随机分为两组:甲组21例患者每次性交时采用动-停-动方法,即同房前充分性爱抚,阴茎全部进入阴道后由不动至缓动至小幅度旋动,待女方将达高潮期时做抽动动作.乙组22例患者除应用行为疗法外,同时口服盐酸氟西汀(美国华生制药有限公司)25 rmg,qn,连用4周.治疗开始后第6周门诊随访,采用SCL-90问卷方式评价治疗前后阴道内射精潜伏期、性交频度、阴茎抽动次数、性欲、总体性交满意度及不良反应发生情况.     

赛乐特治疗早泄的临床研究

目的 :观察抗抑郁剂赛乐特 (盐酸帕罗西汀 )治疗早泄的疗效及副反应。　方法 :每日中午口服赛乐特 2 0mg ,疗程 4周 ;采用《抗抑郁剂治疗早泄疗效评定问卷》并进行修订 ,在治疗前后由病人填写调查问卷和疗效、副作用评价问卷。　结果 :4 3例门诊早泄病人纳入临床研究 ,治疗后病人射精潜伏期、性生活满意度及配偶性生活满意度均有较大改善 ,与治疗前比较 ,差异有极显著性 (P <0 .0 0 1) ;早泄改善起效时间平均为服药后 (11.2 6± 5 .79)d ;32例在停药后平均 (2 0 .94± 8.0 4 )d ,早泄反复到治疗前状态 ;7例病人性欲及性高潮程度升高 ,2例性欲降低 ;少数病人出现便秘、口干、失眠及皮肤瘙痒等不适。　结论 :抗抑郁剂赛乐特对早泄有较好的治疗作用。     

盐酸达泊西汀治疗早泄的临床观察

目的:比较盐酸达泊西汀及舍曲林治疗早泄患者的疗效及不良反应。方法:门诊就诊的早泄患者按2∶1比例随机分配接受盐酸达泊西汀(30 mg,按需服用,n=78)或舍曲林(50 mg,每日1次,n=39)治疗,4周后随访,记录用药前后的阴道内射精潜伏时间(IELT),用药后临床总体印象变化(CGIC)评分,并记录不良反应。结果:经治疗后盐酸达泊西汀组及舍曲林组IELT均显著增加[盐酸达泊西汀:(0.87±0.31)min延长至(2.84±0.86)min;舍曲林:(0.84±0.28)min延长至(2.71±0.92)min]。应用CGIC评分,用药后效果很好或好的比率分别为36.5%及37.5%(盐酸达泊西汀vs舍曲林);CGIC评价有效(很好、好、稍好)的比率分别为63.5%和71.9%。舍曲林组头晕、恶心、头痛及腹泻的发生率稍高于盐酸达泊西汀组但差异不具显著性,但舍曲林组疲劳、嗜睡以及口干的发生率显著高于盐酸达泊西汀组(P0.05)。结论:按需口服盐酸达泊西汀治疗早泄患者安全有效。     

综合治疗单纯性早泄的临床观察

目的:观察综合疗法治疗早泄的临床效果。方法:110例早泄患者随机分成2组:综合治疗组60例(心理、性知识指导,局部涂抹中药酊剂、口服盐酸舍曲林50mg),对照组50例仅口服盐酸舍曲林50mg。以射精潜伏期、夫妻对性生活满意度为疗效判断标准,对治疗4周结束时及停药4周后疗效评估。结果:治疗4周时总有效率综合治疗组为91.6%,对照组为76%,两组比较差异有显著性(P<0.05),停药4周总有效率综合治疗组为68.3%,对照组为42%,两组比较差异有显著性(P<0.01)。结论:应用综合疗法治疗早泄临床效果、效果稳定性满意。     

The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation

PURPOSE: Fluoxetine, a selective serotonin re-uptake inhibitor, has been shown to increase the intravaginal latency of patients with premature ejaculation. We demonstrated the effects of fluoxetine on intravaginal latency, penile sensory threshold, and variables of sacral evoked response and cortical somatosensorial evoked potential in patients with premature ejaculation. MATERIALS AND METHODS: Of 48 patients 40 who presented to our clinic with premature ejaculation met the study criteria, gave written or oral consent, and were divided randomly in a double-blind fashion into 2 groups of 20 patients. The study group received 20 mg. fluoxetine daily and the control group received placebo for 1 month. The patients were evaluated during visits before and after treatment for intravaginal latency, penile sensory threshold values, and the variables of sacral evoked response and cortical somatosensory evoked potential tests. RESULTS: Patient ages, intravaginal latencies, penile sensory threshold values, and amplitudes and latencies of sacral evoked response and cortical somatosensory evoked potential tests in both groups were not significantly different at the beginning of treatment (p >0.05). At the end of treatment intravaginal latencies and penile sensory threshold values were increased in the study group compared to before treatment and the control group (p <0.05). No change was observed in either group for the amplitudes and latencies of sacral evoked response and cortical somatosensory evoked potential tests (p >0.05). CONCLUSIONS: These findings suggest that fluoxetine is effective treatment for premature ejaculation probably due to its effect of increasing the penile sensory threshold, without changing the amplitudes and latencies of sacral evoked response and cortical somatosensory evoked potential.     

EFFICACY AND SAFETY OF FLUOXETINE, SERTRALINE AND CLOMIPRAMINE IN PATIENTS WITH PREMATURE EJACULATION: A DOUBLE-BLIND, PLACEBO CONTROLLED STUDY

Purpose

We compared the efficacy and safety of fluoxetine, sertraline, clomipramine and placebo for the oral pharmacotherapy of premature ejaculation.

Materials and Methods

The study included 36 men (mean age 44 years) who had intravaginal ejaculation latency of less than 2 minutes. Patients took each of 3 drugs and the placebo consecutively during a 4-week period per each agent. Efficacy and side effects data were obtained by a self-reported patient questionnaire that rated intravaginal ejaculation latency, sexual satisfaction of patient and partner, and possible side effects.

Results

After 4 weeks of treatment with placebo, fluoxetine, sertraline and clomipramine the mean intravaginal ejaculation latency time was significantly increased from 46 seconds to 2.27 minutes, 2.30 minutes, 4.27 minutes and 5.75 minutes, respectively (all p <0.01). However, treatment with clomipramine or sertraline caused a greater increase in mean intravaginal ejaculation latency time than fluoxetine or placebo (p <0.01). Patient sexual satisfaction rate after treatment with clomipramine was significantly higher (p <0.05) than with sertraline, fluoxetine or placebo. Partner sexual satisfaction rate was also higher with clomipramine than with sertraline or fluoxetine but no statistical difference was found. The incidence of side effects with clomipramine was significantly higher (p <0.05) compared to that of fluoxetine, sertraline and placebo, while no significant difference among sertraline, fluoxetine and placebo was noted.

Conclusions

In men with premature ejaculation clomipramine was the most useful drug in terms of efficacy. Treatment with sertraline was nearly as effective and had a lower incidence of side effects.     

Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation

INTRODUCTION: The aim of this study was to compare the efficacy of fluoxetine alone and combined with sildenafil in patients complaining of premature ejaculation. PATIENTS AND METHODS: Ninety-one married potent men, 21-43 years old, with premature ejaculation but without any obvious organic cause were enrolled. Pretreatment evaluation included history, physical examination, and self-administration of the International Index of Erectile Function questionnaire. The patients were randomly divided into two groups: group A patients (n = 48) received 20 mg fluoxetine daily for 4 weeks and then 20 mg as needed 2-3 h before sexual activity for 4 months, and group B patients (n = 43) received group A regimen plus 50 mg sildenafil as needed 1 h before sexual activity for 4 months. RESULTS: Ejaculatory latency time and intercourse satisfaction significantly improved in group B as compared with group A (p < 0.05). CONCLUSION: Fluoxetine combined with sildenafil seems to provide significantly better ejaculatory latency time and intercourse satisfaction as compared with fluoxetine alone in patients with premature ejaculation.     

The Efficacy of Fluoxetine in the Treatment of Premature Ejaculation: A Double-Blind Placebo Controlled Study

Purpose

The efficacy of the selective serotonin re-uptake inhibitor fluoxetine in the treatment of premature ejaculation was examined.

Materials and Methods

The study comprised 17 patients with premature ejaculation who presented to the urology clinic of our medical school. In this double-blind study the patients were randomized into treatment groups receiving 20 mg. fluoxetine daily for 1 week and 40 mg. daily afterward (group 1) or 1 capsule placebo daily for 1 week and 2 capsules daily afterward (group 2). The groups were evaluated according to the latent period of intravaginal ejaculation.

Results

The latent period of intravaginal ejaculation in group 1 was significantly longer than that in group 2. Nausea, headache and insomnia were reported side effects.

Conclusions

Fluoxetine may be regarded as a safe and effective alternative in the treatment of premature ejaculation.     

Use of paroxetine on-demand in premature ejaculation

IntroductionIt has been described varied definitions of premature ejaculation (PE), which has determined different prevalences and rates of success for the different therapies with selective serotonin re-uptake inhibitors. Our goal was evaluate the effectiveness of paroxetine like treatment of premature ejaculation administered ondemand (4-6 hours previous to intercourse) compared to the scheme of daily dose.Patients and methodA prospective study type crossover was designed with 14 patients. Grupo A: 7 patient received paroxetine 20 mg /d by three weeks followed by paroxetine 20 mg 4-6 hours before the intercourse by three weeks. Group B: the other 7 patients received the same scheme but replacing by placebo. Later to three weeks of therapy suspension, crossover was made.ResultsThe intravaginal ejaculatory latency time (IELT) pre-treatment was 0,4 minutes. In the group A the IELT average was of 4,3 minutes in the treatment with daily paroxetine; 5,8 minutes when they received paroxetine on-demanad; 0.9 with daily placebo and 0,6 with placebo on-demand (p < 0.001). For group B the IELT during the daily placebo was 0,8 minutes and with placebo on-demand it was of 1,1 . When they received daily paroxetine the IELT was 3,3 minutes and during the phase of paroxetine on-demand it was increased to 6,1 (p<0.001).ConclusionsThe treatment of premature ejaculation with paroxetine in daily dose and scheme on-demand appears similar like effective options.     

The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study

BACKGROUND: Despite the limited number of available study comparing of their efficacy, selective serotonin re-uptake inhibitors (SSRI) have been thought to have beneficial effects for the patients with premature ejaculation. In the present study, we decided to examine the efficacy of citalopram, an SSRI, in the treatment of premature ejaculation. METHOD: The study was consisted of 26 married patients diagnosed with premature ejaculation according to Diagnostic and Statistical Manual of Mental Disorders Third Revised Version (DSM-III-R). The patients were randomly assigned to two groups, citalopram (group I) and placebo (group II), each consisting of 13 patients. The effects of drug on the ejaculatory function were assessed by the intravaginal ejaculation latency time. Additionally, all patients were screened by using Clinical Global Impression-Improvement Scale (CGI-I) and Yonsei Sexual Function Inventory-II (YSFI-II). RESULTS: The increase in the intravaginal ejaculation latency time in the citalopram group was statistically significant than that of placebo group. In addition, with respect to the subscales of the YSFI-II scale, similar overall significant improvements were seen in the patients given citalopram compared to those given placebo. Of group I patients, five (38.5%) were considered as 'very much improved' and four (30.8%) 'much improved' by CGI-I and only one of group II patients (7.7%) showed 'much improved'. CONCLUSION: The patients treated with citalopram showed significantly greater improvement compared to the patients receiving placebo.     

Venlafaxine extended release for the treatment of patients with premature ejaculation: a pilot, single-blind, placebo-controlled, fixed-dose crossover study on short-term administration of an antidepressant drug

In this study, we aimed at evaluating the efficacy and safety of venlafaxine extended release 75 mg, a serotonin and noradrenaline reuptake inhibitor, in the treatment of patients with premature ejaculation. Thirty-one patients with intravaginal ejaculation latency of less than 2 min received venlafaxine XR (75 mg/day) or placebo during a 2-week period for each agent with a washout period of 1 week between agents. Efficacy was assessed for each agent with changes in ejaculation latency measured with a stopwatch and sexual satisfaction scores of patients and partners. Side-effects, pre- and post-treatment levels of biochemical and spermiogram parameters, follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin and total testosterone were recorded for each agent. Statistical analysis was performed on 21 patients. After 2 weeks of treatment with placebo and venlafaxine, ejaculation latency time was significantly increased from 60.1 +/- 39.1 to 126.9 +/- 98.3 sec and to 178.1 +/- 122.8 sec, respectively (p < 0.0001 for each one). However, the difference between the two agents was insignificant (p = 0.144). Venlafaxine and placebo increased sexual satisfaction scores of both patients and partners similarly, no statistically significant difference was found between them in this respect. The incidence of side-effects with venlafaxine was indifferent than that of placebo (p > 0.1) except nausea (p = 0.035). Both agents did not change the blood and spermiogram parameters significantly, except FSH increases. Short-term use of venlafaxine XR 75 mg has only a placebo effect on ejaculation latency and sexual satisfaction scores, therefore, is not appropriate for the patients with premature ejaculation. Further dose-time studies are required to draw final conclusions on the inefficacy of this drug in premature ejaculation.     

西地那非、舍曲林合用与舍曲林单用治疗早泄的疗效比较

目的:比较联合应用西地那非和舍曲林治疗早泄与单用舍曲林治疗早泄的疗效及不良反应。方法:本院男科门诊无器质性病变的早泄患者72例,年龄18~42岁,平均32.4岁,随机分成A、B组,每组36例,A组口服舍曲林50mg,1次/d,性生活前4~6h服用;B组除了同样服用舍曲林外,在性生活前1h左右加用西地那非50mg,共观察12周。比较两组治疗前后的平均阴道内射精潜伏期、国际勃起功能指数(IIEF)问卷中的性交满意度评分、每周性交频率以及治疗期间的不良反应,并评估在疗程结束时,患者及其配偶对性生活的满意程度。结果:A、B两组患者平均阴道内射精潜伏期在治疗后均显著增加,而B组较A组增加更显著(P<0.05);治疗后IIEF问卷中的性交满意度评分在A、B组均有显著性提高,B组较A组改善更明显(P<0.05);治疗后每周性交频率两组均显著增多,两组之间比较B组增加更明显(P<0.05)。治疗结束时,A组患者对性生活感到满意的有20例(55.6%),B组有28例(77.8%),B组满意比例较A组显著增高(P<0.05)。在不良反应方面,B组患者头痛、头晕(P<0.01)和潮红(P<0.001)的发生率较A组要高。结论:在对早泄患者的治疗上,联合应用西地那非和舍曲林比单用舍曲林疗效要好,但同时引起的不良反应也稍有增加。     

TREATMENT OF PREMATURE EJACULATION WITH PAROXETINE HYDROCHLORIDE AS NEEDED: 2 SINGLE-BLIND PLACEBO CONTROLLED CROSSOVER STUDIES

PURPOSE: We evaluate the efficacy of paroxetine hydrochloride as needed for the treatment of premature ejaculation. MATERIALS AND METHOD: Study 1 comprised 26 potent men with a mean age of 39.5 years with premature ejaculation who were randomized to receive 20 mg. oral paroxetine (group A) or placebo (group B) as needed 3 to 4 hours before planned intercourse in a controlled single-blind crossover trial. Study 2 comprised 42 potent men with a mean age of 40.5 years with premature ejaculation who were randomized to receive 10 mg. paroxetine daily for 3 weeks and then 20 mg. paroxetine as needed (group C) for 4 weeks or placebo daily for 3 weeks and then placebo as needed (group D) for 4 weeks. RESULTS: Mean pretreatment ejaculatory latency time was 0.3 minute for study 1. At 4 weeks mean ejaculatory latency time was 3.2 minutes in the paroxetine as needed and 0.45 in the placebo as needed phase for group A (p < 0.001), and 0.6 in the placebo as needed and 3.5 in the paroxetine as needed phase for group B (p < 0.001). There were no adverse effects with paroxetine or placebo in study 1. Mean pretreatment ejaculatory latency time was 0.5 minute for study 2. At 3 weeks mean ejaculatory latency time was 4.3 minutes in the paroxetine daily and 5.8 in the paroxetine as needed phase, and 0.9 in the placebo daily and 0.6 in the placebo as needed phase for group C (p < 0.001). At 3 weeks mean ejaculatory latency time was 0.8 minutes in the placebo daily and 1.1 in the placebo as needed phase, and 3.3 in the paroxetine daily and 6.1 in the paroxetine as needed phase for group D (p < 0.001). Adverse effects in 7 of 42 men (17%) given paroxetine daily included an ejaculation in 3, anorexia in 1, gastrointestinal upset in 3 and reduced libido in 2. Mean ejaculatory latency time was greater in the paroxetine as needed phase of study 2 than that of study 1 (p < 0.05), suggesting that ejaculatory control achieved with paroxetine as needed is significantly better if patients are initially treated with the drug daily. CONCLUSIONS: Paroxetine appears to be superior to placebo in the pharmacological treatment of premature ejaculation when administered on a chronic or as needed basis.